Hostname: page-component-8448b6f56d-42gr6 Total loading time: 0 Render date: 2024-04-20T03:04:17.327Z Has data issue: false hasContentIssue false
  • English
  • Français

Intensive symptom control of opioid-refractory dyspnea in congestive heart failure: Role of milrinone in the palliative care unit

Published online by Cambridge University Press:  24 April 2015

Julio Silvestre ,
Maria Montoya ,
Eduardo Bruera  and
Ahmed Elsayem
Julio Silvestre
Affiliation:
Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Maria Montoya
Affiliation:
Department of Palliative Care and Rehabilitation Medicine, The University of Texas MD Anderson Cancer Center, Houston. Texas
Eduardo Bruera
Affiliation:
Department of Palliative Care and Rehabilitation Medicine, The University of Texas MD Anderson Cancer Center, Houston. Texas
Ahmed Elsayem*
Affiliation:
Department of Emergency Medicine and Department of Palliative Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
*
Address correspondence and reprint requests to: Ahmed Elsayem, Emergency Medicine Department, The University of Texas MD Anderson Cancer Center, Unit 1468, Post Office Box 301402, Houston, Texas 77230-1402. E-mail: aelsayem@mdanderson.org
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

We describe an exemplary case of congestive heart failure (CHF) symptoms controlled with milrinone. We also analyze the benefits and risks of milrinone administration in an unmonitored setting.

Method:

We describe the case of a patient with refractory leukemia and end-stage CHF who developed severe dyspnea after discontinuation of milrinone. At that point, despite starting opioids, she had been severely dyspneic and anxious, requiring admission to the palliative care unit (PCU) for symptom control. After negotiation with hospital administrators, milrinone was administered in an unmonitored setting such as the PCU. A multidisciplinary team approach was also provided.

Results:

Milrinone produced a dramatic improvement in the patient's symptom scores and performance status. The patient was eventually discharged to home hospice on a milrinone infusion with excellent symptom control.

Significance of Results:

This case suggests that milrinone may be of benefit for short-term inpatient administration for dyspnea management, even in unmonitored settings and consequently during hospice in do-not-resuscitate (DNR) patients. This strategy may reduce costs and readmissions to the hospital related to end-stage CHF.

Keywords

Congestive heart failureOpioid-refractory dyspneaPalliative careMilrinone
Type
Case Reports
Information
Palliative & Supportive Care , Volume 13 , Issue 6 , December 2015 , pp. 1781 - 1785
Copyright
Copyright © Cambridge University Press 2015 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

Benotti, J.R., Lesko, L.J., McCue, J.E., et al. (1985). Pharmacokinetics and pharmacodynamics of milrinone in chronic congestive heart failure. The American Journal of Cardiology, 56, 685–689.Google Scholar
Caraceni, A., Zecca, E., Martini, C., et al. (2012). Palliative sedation at the end of life at a tertiary cancer center. Supportive Care in Cancer, 20, 1299–1307.Google Scholar
Cesario, D., Clark, J. & Maisel, A. (1998). Beneficial effects of intermittent home administration of the inotrope/vasodilator milrinone in patients with end-stage congestive heart failure: A preliminary study. American Heart Journal, 135, 121–129.Google Scholar
Charisopoulou, D., Leaver, N. & Banner, N.R. (2014). Milrinone in advanced heart failure: Dose and therapeutic monitor outside intensive care unit. Angiology, 65(4), 343–349.Google Scholar
Chochinov, H.M., Hack, T., Hassard, T., et al. (2005). Understanding the will to live in patients nearing death. Psychosomatics, 46, 7–10.Google Scholar
Currow, D.C., Plummer, J., Frith, P., et al. (2007). Can we predict which patients with refractory dyspnea will respond to opioids? Journal of Palliative Medicine, 10, 1031–1036.CrossRefGoogle ScholarPubMed
Felker, G.M. & O'Connor, C.M. (2001). Inotropic therapy for heart failure: An evidence-based approach. American Heart Journal, 142, 393–401.CrossRefGoogle ScholarPubMed
Go, A.S., Mozaffarian, D., Roger, V.L., et al. (2013). Heart disease and stroke statistics: 2013 update. A report from the American Heart Association. Circulation, 127, e6–e245.Google Scholar
Gupta, D., Lis, C.G. & Grutsch, J.F. (2007). The relationship between dyspnea and patient satisfaction with quality of life in advanced cancer. Supportive Care in Cancer, 15, 533–538.Google Scholar
Hajiro, T., Nishimura, K., Tsukino, M., et al. (1999). A comparison of the level of dyspnea vs. disease severity in indicating the health-related quality of life of patients with COPD. Chest, 116, 1632–1637.CrossRefGoogle ScholarPubMed
Heidenreich, P.A., Trogdon, J.G., Khavjou, O.A., et al. (2011). Forecasting the future of cardiovascular disease in the United States: A policy statement from the American Heart Association. Circulation, 123, 933–944.Google Scholar
Holm, K.E., Bowler, R.P., Make, B.J., et al. (2009). Family relationship quality is associated with psychological distress, dyspnea, and quality of life in COPD. COPD, 6, 359–368.Google Scholar
Holmes, J.R., Kubo, S.H., Cody, R.J., et al. (1985). Milrinone in congestive heart failure: Observations on ambulatory ventricular arrhythmias. American Heart Journal, 110, 800–806.Google Scholar
Honerjager, P. (1991). Pharmacology of bipyridine phosphodiesterase III inhibitors. American Heart Journal, 121, 1939–1944.Google Scholar
Jencks, S.F., Williams, M.V. & Coleman, E.A. (2009). Rehospitalizations among patients in the Medicare fee-for-service program. The New England Journal of Medicine, 360, 1418–1428.Google Scholar
Karapolat, H., Eyigor, S., Atasever, A., et al. (2008). Effect of dyspnea and clinical variables on the quality of life and functional capacity in patients with chronic obstructive pulmonary disease and congestive heart failure. Chinese Medical Journal, 121, 592–596.Google Scholar
Laoutaris, I., Dritsas, A., Brown, M.D., et al. (2004). Inspiratory muscle training using an incremental endurance test alleviates dyspnea and improves functional status in patients with chronic heart failure. European Journal of Cardiovascular Prevention and Rehabilitation, 11, 489–496.Google Scholar
Majure, D.T. & Teerlink, J.R. (2011). Update on the management of acute decompensated heart failure. Current Treatment Options in Cardiovascular Medicine. October 6. Epub ahead of print.CrossRefGoogle Scholar
Malek, M. (1999). Health economics of heart failure. Heart, 82(Suppl. 4), IV11–IV13.CrossRefGoogle ScholarPubMed
Marius-Nunez, A.L., Heaney, L., Fernandez, R.N., et al. (1996). Intermittent inotropic therapy in an outpatient setting: A cost-effective therapeutic modality in patients with refractory heart failure. American Heart Journal, 132, 805–808.Google Scholar
Mercadante, S., Intravaia, G., Villari, P., et al. (2009). Controlled sedation for refractory symptoms in dying patients. Journal of Pain and Symptom Management, 37, 771–779.CrossRefGoogle ScholarPubMed
Milfred-LaForest, S.K., Shubert, J., Mendoza, B., et al. (1999). Tolerability of extended duration intravenous milrinone in patients hospitalized for advanced heart failure and the usefulness of uptitration of oral angiotensin-converting enzyme inhibitors. The American Journal of Cardiology, 84, 894–899.CrossRefGoogle ScholarPubMed
O'Connell, J.B. & Bristow, M.R. (1994). Economic impact of heart failure in the United States: Time for a different approach. The Journal of Heart and Lung Transplantation, 13, S107–S112.Google Scholar
Oosten, A.W., Oldenmenger, W.H., van Zuylen, C., et al. (2011). Higher doses of opioids in patients who need palliative sedation prior to death: Cause or consequence? European Journal of Cancer, 47, 2341–2346.Google Scholar
Packer, M., Carver, J.R., Rodeheffer, R.J., et al. (1991). Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. The New England Journal of Medicine, 325, 1468–1475.Google Scholar
Parshall, M.B., Schwartzstein, R.M., Adams, L., et al. (2012). An official American Thoracic Society statement: Update on the mechanisms, assessment, and management of dyspnea. American Journal of Respiratory and Critical Care Medicine, 185, 435–452.Google Scholar
Solano, J.P., Gomes, B. & Higginson, I.J. (2006). A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. Journal of Pain and Symptom Management, 31, 58–69.Google Scholar
Titler, M.G., Jensen, G.A., Dochterman, J.M., et al. (2008). Cost of hospital care for older adults with heart failure: Medical, pharmaceutical, and nursing costs. Health Services Research, 43, 635–655.Google Scholar
Vazir, A., Leaver, N., Lyster, H., et al. (2011). Is monitoring milrinone therapy useful in advanced heart failure? International Journal of Cardiology, 149, 380–381.Google Scholar
Whellan, D.J., Cox, M., Hernandez, A.F., et al. (2012). Utilization of hospice and predicted mortality risk among older patients hospitalized with heart failure: Findings from GWTG–HF. Journal of Cardiac Failure, 18, 471–477.Google Scholar